Vinmec performs its first total femoral replacement for world's youngest cancer patient
Refusing to Surrender to Fate
In October 2022, after a minor fall, Tran Minh Duc (a boy from Ho Chi Minh City) hurt his left thigh. Believing it to be just a simple injury, his family was shocked to hear the bad news from the doctor: The boy was diagnosed with osteosarcoma - a malignant bone cancer with a tumor that had invaded his entire femur. It is typically seen in adolescents, but rare and haphazard in younger children.
Given the severe prognosis, most medical facilities recommended amputation to ensure his survival or bone grafting (a conventional method). Both methods carry a high risk of rejection and infection, especially for younger children in the development stage.
The flash of hope appeared when she met Prof. Dr. Tran Trung Dung - Director of the Orthopedic Council, Vinmec Healthcare System. An unprecedented approach was proposed to apply to such a young patient: replacing the entire femur with personalized 3D-printed materials that are produced in Vietnam.
A "Legendary" Surgery with Vietnamese Technologies
According to Prof. Dr. Tran Trung Dung, the entire femur of Duc has been invaded by the tumor. To ensure his life, Duc's leg had to be amputated. However, different types of artificial joints available on the market are not compatible with young bodies.
After various interdisciplinary case conferences including Orthopedics, Oncology, Diagnostic Imaging, Pathology, Clinical Pharmacy, etc., the Vinmec experts reached a consensus on the optimal approach - a two-phase surgery. Phase 1 (January 2024): Removing the tumor and temporarily grafting a cement bone. Phase 2 (May 2025): Replacing the entire femur with a "customized" bone made of 3D-printed metal.
On January 29, 2024, Duc underwent his first surgery - removing the entire tumor and temporarily grafting a cement bone. In May 2025 when his conditions had stabilized, Duc's entire femur was replaced with a "customized" bone made of 3D-printed metal. For the first time, 3D printing was applied to the youngest patient in the world with the collaboration between Vinmec medical professionals and VinUni's engineers. The bone's design is modular, enabling future extensions based on the child's physical development.
According to MSc. Dr. Tran Duc Thanh, who was directly engaged in the surgery:"We contacted foreign manufacturers but there was no suitable design. Self-manufacturing the equipment allows us to be proactive in treatment, it also paves the way for a new direction for Vietnamese medicine."
Prof. Dr. Tran Trung Dung added: "The 4-hour surgery was a success. Duc recovered quickly without any complications, now he is able to walk with the support of physical therapy. The surgery represented a breakthrough in complex techniques and the evidence for sound collaboration in the multidisciplinary medical team. Both the life and limb of the child were kept intact."
Vinmec - Pioneering in Vietnam's Personalized Precision Medicine
Once at risk of amputation and life-long dependence, Minh Duc is now able to walk on his own feet, supported by physical therapy without any complications of infection or transplant rejection. Every step Duc takes is a testament to precision medicine, advanced technologies, and the unwavering love of his mother.
"When my son stood up, I was trembling with joy. He has been unable to walk for nearly two years. Now he did it. I just hope that he will be capable of riding a bike and playing football like his peers..." - Ms. Hoang said in tears.
Prof. Dr. Tran Trung Dung also shared his emotions:"We believe that modern medicine and compassion should go side by side. Duc is not just a special patient, his case represents a story of determination, maternal love, and the faith that the impossible can become possible if we never give up."
Vinmec is the first Vietnamese healthcare system that applies personalized 3D printing in the treatment of musculoskeletal conditions. Instead of using standardized equipment, Vinmec uses CT and MRI data in the design of artificial joints and bones tailored to each patient to optimize motor functions, enhance precision, and reduce the recovery period.
To date, Vinmec has achieved successes in many difficult and rare cases, e.g. liver transplantation for an 8-month-old patient from a brain-dead donor, the first in Southeast Asia to reproduce 3D-printed titanium chest wall, and the first in the world to replace the pelvis and femur at the same time with 3D-printed bones.
With its series of breakthroughs and pioneering achievements in high-tech healthcare and precision medicine, Vinmec further affirms the aspiration to elevate the position of Vietnam in the global medical field.
Vinmec - A Place of Healing and Reimagining the Future.
Hashtag: #Vinmec
https://www.vinmec.com/eng/
The issuer is solely responsible for the content of this announcement.
About Vinmec Healthcare System
Vinmec is Vietnam's leading private healthcare system, with a network of 9 hospitals nationwide, developed to international standards with a focus on comprehensive, personalized, and specialty care. Its proud achievements include:
A strategic partnership with Cleveland Clinic, one of the world's top healthcare systems, enabling global clinical collaboration and access to world-class medical standards.
No.1 Healthcare Services for Foreigners in Vietnam, trusted by international residents for its high-quality care, globally trained physicians, and international-standard facilities.
The only healthcare system in Asia honored at the Healthcare Asia Awards 2025, receiving two prestigious accolades: Hospital Group of the Year and Technology Innovation of the Year, reinforcing its leadership in the region.
JCI-accredited, meeting the world's most rigorous standards for patient safety and healthcare quality.
The first and only healthcare system in Vietnam to establish Centers of Excellence (CoEs) across four key specialties: Cardiology, Oncology, Orthopedics & Sports Medicine, and Clinical Immunology – Allergy.
For medical inquiries, please contact: v.medtour@vinmec.com
Vinmec
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Zawya
6 days ago
- Zawya
Vinmec Central Park Performs Vietnam's First SEEG using AutoGuide Robotic Guidance System for a child diagnosed from refractory epilepsy
HO CHI MINH CITY, VIETNAM - Media OutReach Newswire - 29 July 2025 – A major breakthrough in Vietnam's neurological treatment was recently achieved as doctors at Vinmec Central Park International Hospital successfully performed surgery on a 9-year-old boy with drug-resistant epilepsy, utilizing the AutoGuide™ robotic Guidance system for SEEG implantation. This marks the first time in Vietnam that robotic guidance has been used in pediatric epilepsy surgery, — a milestone that opens new possibilities for safer, less invasive, and highly precise treatment options for vulnerable patients. The case also highlights Vietnam's progress in approaching global standards in advanced epilepsy care. A 5-Year Search for Seizure-Free Sleep The patient, B.Q.K. (age 9, from Hanoi), began experiencing seizures in 2021. Despite various treatment regimens and adjustments both domestically and abroad, his condition failed to improve - sometimes experiencing dozens of seizures per day. For nearly five years, his family sought treatment at numerous medical centers in the hope of giving their child a peaceful night's sleep without seizures. According to the World Health Organization (WHO), approximately 30% of epilepsy patients are drug-resistant (1), meaning they do not respond to medication. For these patients, surgery resection of the epileptic zone is often the most effective option. However, accurately localizing the epileptogenic zone - especially in children - is extremely challenging when scalp EEG, MRI, or PET scans provide inconclusive findings. SEEG and AutoGuide: A Technological Duo to Precisely Locate the "Culprit" in the Brain Following a thorough multidisciplinary evaluation, doctors at Vinmec Central Park decided to use AutoGuide™ robotic navigation system to perform stereo-electroencephalography (SEEG) to accurately identify the epileptic zone. The robotic guidance ensured high accuracy, faster operative time, and reduced trauma to the brain. After seven days of SEEG monitoring, the epileptogenic zone was localized in the right orbitofrontal cortex and inferior frontal gyrus—areas densely packed with neural pathways and blood vessels. On June 17, 2025, the epileptic zone removal was performed by Dr. Truong Van Tri and his team at Vinmec Central Park, with technical support from Assoc. Prof. Dr. Shunsuke Nakae, an epilepsy specialist from Japan. The surgery was successful, with no postoperative neurological deficits. After more than one month of recovery, the patient resumed normal activities and play, with only two minor nocturnal seizures recorded - a reduction of over 95% compared to preoperative frequency. " For the first time, we achieved near-perfect outcome in pediatric epilepsy surgery thanks to AutoGuide™. This is a critical milestone, especially for young patients who are highly vulnerable to major brain surgery," said Dr. Tri. Vinmec: Advancing Neurology with Technology and International Integration This successful case exemplifies Vinmec's strategy to build centers of medical excellence through the integration of advanced technology, multidisciplinary expertise, and individualized treatment protocols. Vinmec has been ranked as the No.1 private hospital system in Vietnam for expatriates and international visitors, according to independent patient satisfaction surveys. Vinmec Central Park is currently one of the few healthcare facilities in Vietnam, placing Vietnam among the few countries in Asia to master this technique—narrowing the gap with global neurology leaders. (1) Hashtag: #Vinmec The issuer is solely responsible for the content of this announcement. About Vinmec Health System Vinmec is a nonprofit healthcare system founded by Vingroup, one of Vietnam's largest private conglomerates. With 9 international hospitals and 4 international clinics nationwide, Vinmec is committed to delivering international-standard healthcare through subspecialized care, personalized treatment, and cutting-edge medical technology. Vinmec Central Park in Ho Chi Minh City is the flagship hospital in the network and has been widely recognized as the top private hospital in Vietnam for expatriates and international patients, serving tens of thousands annually. The hospital excels across several specialties: Neurosurgery & Epilepsy: SEEG, robotic-guided surgery, brain tumor resection Oncology – Orthopedic Surgery – Cardiology – Advanced Obstetrics & Gynecology Allergy & Clinical Immunology: Vietnam's first and only center recognized as a Center of Excellence by the World Allergy Organization (WAO), in close partnership with Cleveland Clinic (USA) to develop precision medicine and chronic disease management programs 3D Medical Technology: Pioneer in 3D-printed titanium implants for complex orthopedic oncology reconstructions Vinmec

Emirates 24/7
24-07-2025
- Emirates 24/7
Dubai Health scientists publish first Arab Pangenome Reference, marking a milestone for precision medicine
Scientists at the Mohammed Bin Rashid University of Medicine and Health Sciences (MBRU), the learning and discovery arm of Dubai Health, have published the first Arab Pangenome Reference, marking a major milestone in both regional and global genomic research. The study, released in Nature Communications, a leading scientific journal, provides a crucial foundation for advancing precision medicine and personalised healthcare for Arab populations, while also supporting the UAE's National Genome Strategy, a 10-year initiative launched in 2023 by the Emirates Genome Council to advance personalised, preventive, and precision healthcare through cutting-edge genomic science. The reference was built using high-quality DNA sequencing from 53 people of diverse Arab backgrounds in the UAE. The work, conducted in MBRU's state-of-the-art Center for Applied and Translational Genomics (CATG), uncovered over 110 million base pairs of novel DNA sequences and identified nearly nine million small differences and more than 235,000 larger structural differences specific to Arab populations that have not been reported before. These findings are significant, as global DNA references have historically underrepresented Arab populations — a gap this research helps to close. The Arab Pangenome Reference supports national and regional precision medicine initiatives by enabling the development of population-specific biomarkers, risk models, and therapeutic targets. One notable discovery was the duplicated gene TAF11L5, found highly enriched in Arab individuals studied but absent from global references. This gene may play a role in regulating other genes and could have implications for understanding disease risk and individual variation in treatment response. Professor Alawi Alsheikh-Ali, Director General, Dubai Health Authority, and co-author of the study, said: 'This achievement strengthens the UAE's position in genomic science. By building a reference that reflects the genetic diversity of Arab populations, we are enabling more precise and equitable healthcare. It's a foundational step towards realising the goals of our National Genome Strategy and ensuring that future medical innovations are shaped by data from our own communities.' Dr. Hanan Al Suwaidi, Acting Provost of MBRU, and co-author of the study said: 'The capabilities of the CATG lab were central to the success of this project. From genetic sequencing to advanced bioinformatics, every stage of the research was completed in-house. This level of integration gave us full control over quality and timelines, reflecting Dubai Health's commitment to building world-class infrastructure and fostering national scientific leaders." While genomic research has advanced rapidly over the past two decades, much of the foundational data has come from a narrow subset of global populations. This has created blind spots in how genetic risk is understood and addressed across different communities. The Arab Pangenome Reference contributes to a growing international effort to correct this imbalance by introducing high-quality data from a historically underrepresented population. Dr. Mohammed Uddin, Director of CATG and Associate Professor of Genetics at MBRU, and senior author of the study, said: 'This pangenome reference marks a major advancement in our understanding of Arab genomic diversity. It serves as a critical resource for both research discovery and clinical genome diagnostics, with lasting impact for future generations across the region.' The project also developed 'PanScan', a bioinformatics tool to support more complex analysis of human pangenomes. Although not the central focus of the study, PanScan enables researchers to detect gene duplications, novel DNA changes, and complex DNA structures. Now publicly available on GitHub, a common resource used by scientists worldwide, the tool was created to support the Arab Pangenome Reference and similar efforts globally. Dr. Nasna Nassir, lead author of the study and Assistant Professor at MBRU, said: 'To support the Arab Pangenome Reference study, we developed PanScan, a tool designed to identify novel variants, gene duplications, and complex haplotype patterns specific to Arab populations. PanScan was key to uncovering unique genomic insights in our study and is now publicly available to support similar research globally.' The research reflects Dubai Health's commitment to advancing learning and discovery through MBRU. The university's research strategy is focused on contributing to global scientific progress. By investing in foundational genomic research, Dubai Health is helping to ensure that Arab populations are represented in the future of precision healthcare. The full study is available at:


Zawya
09-07-2025
- Zawya
BioSapien extends pre-Series A funding round to $8mln
UAE – BioSapien has extended its pre-Series A round to over $8 million, adding Globivest to its list of backers, alongside Global Ventures, Golden Gate Ventures, and Dara Holdings. Globivest is the first women-led, gender lens venture capital fund from the MENA region, according to a press release. The healthtech platform also announces the acquisition of world-class talent with 12 new appointments, including Zhiyu Xia PhD as Senior Manufacturing Engineer, Gaurav Vij MBA as Business Officer, and Nancy Sperling MS MS as the QC Lead. Founded in 2018, BioSapien offers a flagship product, MediChip™, which is a drug delivery, 3D-printed, slow-release delivery platform attachable to any tissue with minimal systemic side effects. Khatija Ali, CEO of BioSapien, said: 'Two of the greatest challenges for young, fast-growing companies are establishing a strong balance sheet and attracting high-quality talent. Therefore, I am delighted to announce an extension of BioSapien's pre-Series A funding round.' She added: 'A business is only as good as its people - so it is thrilling to be joined by such high-quality, diverse talent. Together, we will shape a future where precision medicine is both globally impactful and locally accessible.' In January 2025, BioSapien extended its pre-Series A funding round to $7 million to tackle escalating cancer rates by leveraging advanced 3D printing technology. During December 2024, the biotech company secured a $5.50 million pre-Series A funding round. All Rights Reserved - Mubasher Info © 2005 - 2022 Provided by SyndiGate Media Inc. (